Breast Cancer

View overview page
0:44
ADCs in early breast cancer
Sung-Bae Kim • 11 May 2023
3:24
What to look forward to in breast cancer at ASCO 2023
Hope Rugo • 12 May 2023
1:48
Navigating treatment decisions for patients with HR+/ HER- mBC
Komal Jhaveri • 11 May 2023
2:06
Exploring novel therapeutic approaches in HR+/ HER2- mBC
Komal Jhaveri • 11 May 2023
3:15
Investigating targeted therapy combinations in metastatic HR+ breast cancer
Komal Jhaveri • 11 May 2023
1:23
Latest advances in immuno-oncology research in ER+ breast cancer
Justin Balko • 12 May 2023
0:55
Prognostic biomarkers of immunotherapy efficacy in breast cancer
Justin Balko • 12 May 2023
3:55
Is it possible to predict who will benefit the most from IO in TNBC?
Justin Balko • 12 May 2023
0:43
Addressing the underrepresentation of ILC in clinical trials
Karen Van Baelen • 12 May 2023
1:17
ILC: a commonly overlooked subtype of breast cancer
Karen Van Baelen • 12 May 2023
0:41
Investigating the influence of HER2 low status in LBC
Karen Van Baelen • 12 May 2023
1:11
Development of antibody-drug conjugate therapies in breast cancer
Heather McArthur • 12 May 2023
1:22
HER2DX risk-score in early-stage HER2-positive breast cancer
Guillermo Villacampa Javierre • 12 May 2023
1:07
HR status in determining the efficacy of platinum therapy in advanced TNBC
Tira Tan • 12 May 2023
6:33
Detailed safety analysis from the DESTINY-Breast04 trial
Hope Rugo • 12 May 2023
1:49
Phase Ib data CAPItello-292: capivasertib + palbociclib + fulvestrant in HR+/HER2- breast cancer
Patrick Neven • 11 May 2023

The Breast Cancer Channel on VJOncology is supported by Gilead.

These supporters have no influence over the production of the content.

If you are interested in becoming a supporter of The Breast Cancer Channel, please contact us.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals